blackboard1965 /
26 August 2016Asia

Mylan biosimilar application moves forward

The European Medicines Agency has accepted pharmaceutical company Mylan’s request to review its application for a biosimilar of Herceptin (trastuzumab).

The drug, developed by Roche, is used to treat breast and gastric cancers.

The acceptance marks the second time that Mylan, along with its partner company Biocon, has had its calls for a review of a biosimilar application accepted in Europe.

A marketing authorisation application for a biosimilar of Amgen’s Neulasta (pegfilgrastim) was also accepted for review last month.

Arun Chandavarkar, CEO of Biocon, said:  “The regulatory submission for proposed biosimilar Trastuzumab in Europe takes us a step closer towards enabling affordable access to this critical biologic therapy for the treatment of HER2-positive breast cancer.”

Rajiv Malik, president of Mylan, added: “Europe represents a key market for more affordable versions of these im portant products, as governments across the region strive to reduce healthcare costs. We look forward to continuing to work to bring this product to patients upon approval.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at